ArticleWorld journal of surgical oncology2025
Outcomes and survival trends following pelvic exenteration for locally advanced and recurrent rectal cancer: a 20-Year analysis from a tertiary cancer center in India.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exenterative Surgery in Advanced Pelvic Cancer: Survival Outcomes and an Exploratory Predictive Modeling Framework for Surgical Decision Support.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPelvic exenteration (PE) offers a potential cure for selected patients with Locally Advanced Rectal Cancer (LARC) or Locally Recurrent Rectal Cancer (LRRC) invading adjacent pelvic organs. Despite advances in surgical technique and perioperative care, PE remains associated with significant morbidity. This study evaluates long-term oncologic outcomes of PE over 20 years at a high-volume tertiary cancer center in India.
methodsWe retrospectively analysed 97 patients who underwent PE between January 2000 and December 2020. Patients included those with LARC or LRRC, where R0 resection was deemed feasible. Surgical procedures were classified as total pelvic exenteration (TPE) or modified pelvic exenteration (MPE). Data on demographics, operative parameters, pathological features, recurrence pattern and survival were analysed.
resultsAmong the 97 patients (median age 59; 80.4% male), 67% had LARC and 33% LRRC. R0 resection was achieved in 71.1%. TPE was more common in LRRC, while MPE predominated in LARC (p = 0.014). Common complications included pelvic collection (25.8%) and wound infection (15.5%). The 5-year OS was higher in R0 resection patients (51.9% vs. 12.9%; p = 0.013) and those with LARC vs. LRRC (57.0% vs. 10.6%; p = 0.032). LRRC had higher recurrences post R0 resection. In the multivariate analysis, the only independent predictors of OS were the initial presentation of the disease and R0 resection.
conclusionPE remains a curative strategy for LARC and LRRC following an R0 resection. LRRC is associated with higher recurrence and poorer survival. Optimal outcomes require multidisciplinary evaluation, margin-negative resection, and tailored surgical approaches. This study provides data from a low- and middle-income country setting, where such literature remains limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.